SAMHD1, the unique dNTP triphosphohydrolase described in humans, has been proposed to play a key role in hematological cancers, although its value in advanced solid tumors has not yet been explored. This evidence concerns the gene SAMHD1 and hematopoietic and lymphoid cell neoplasm.